Avadel Pharma
AVDL21.6400.00% ( 0.000 )
Avadel Pharma (AVDL)
Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is the LUMRYZ, a formulation of sodium oxyba...
- Open
- --
- High
- --
- Low
- --
- Prev. Close
- 21.640
- Volume
- 0
- Turnover
- 0
- Avg Price
- --
- Bid/Ask Ratio
- --
- Amplitude
- --
- 52wk High
- 23.570
- Volume Ratio
- 0.00
- Turnover Ratio
- --
Avadel Pharma Analyst Rating
View MoreForecast & Rating
Feb 2, 2026Price forecast
$20.94-3.25%
Forecast & RatingHold
10analysts
- Strong buy0.00%
- Buy0.00%
- Hold100.00%
- Sell0.00%
- Strong sell0.00%
News
- Quartr · 2 days ago, 06:47 AM
ALKS: Q2 2026 revenue and profitability surged following the Avadel acquisition and product growth
- TradingView · 2 days ago, 06:13 AM
Alkermes reports Q2 2026 revenue $496.0M, GAAP net income $0.5M, Adjusted EBITDA $139.2M
- Market Beat · Jun 10 at 01:08 PM
Alkermes Touts Orexin Ambitions as Alixorexton Enters Phase 3 and CEO Transition Nears
- Market Beat · Mar 2 at 09:02 PM
Alkermes Pivots Deeper Into Sleep Medicine After Avadel Deal, Details Orexin Phase 3 at TD Cowen
- StockTitan · Feb 24 at 09:55 PM
Alkermes plc Announces CEO Succession Plan | ALKS Stock News
- London Stock Exchange · Feb 13 at 08:34 AM
REG - Goldman Sachs & Co. Avadel Pharma plc - Form 38.5b - Avadel Pharmaceuticals PLC
